{"abstract": "Merck will pay $24.50 a share in cash, or about $3.85 billion, for the biotechnology company Idenix in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area.", "web_url": "https://dealbook.nytimes.com/2014/06/09/merck-to-acquire-idenix-pharmaceuticals/", "snippet": "Merck will pay $24.50 a share in cash, or about $3.85 billion, for the biotechnology company Idenix in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area.", "lead_paragraph": "Updated, 8:32 p.m. | Merck will buy the biotechnology company Idenix Pharmaceuticals for $3.85 billion in an effort to bolster its arsenal of potential drugs in the competitive arena of hepatitis C treatments, the companies announced on Monday.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/10/business/Merck/Merck-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/06/10/business/Merck/Merck-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/10/business/Merck/Merck-jumbo.jpg", "height": 682, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/10/business/Merck/Merck-superJumbo.jpg", "height": 853, "width": 1280, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/10/business/Merck/Merck-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/06/10/business/Merck/Merck-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/10/business/Merck/Merck-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Merck Bids $3.8 Billion for an Edge in Hepatitis", "kicker": "DealBook", "content_kicker": null, "print_headline": "Merck Bids $3.8 Billion for an Edge in Hepatitis", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "subject", "value": "Sovaldi (Drug)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Idenix Pharmaceuticals Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Merck & Company Inc", "rank": 5, "major": "N"}], "pub_date": "2014-06-09T11:42:40+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4ac748bf-67e9-5ea0-8ee7-c1df0b20c885", "word_count": 869, "uri": "nyt://article/4ac748bf-67e9-5ea0-8ee7-c1df0b20c885"}